Workflow
Centene(CNC)
icon
Search documents
Centene Corporation (CNC) Shares Fall ~10% Pre-Market After Reporting Q2 2025 Diluted Loss Per Share, Class Action Lawsuit Over “Inflated Guidance” Pending – Hagens Berman
GlobeNewswire News Room· 2025-07-28 20:36
Core Viewpoint - Centene Corporation experienced a significant decline in stock price following the release of disappointing Q2 2025 financial results, leading to a class action lawsuit from investors alleging misleading statements about the company's financial health and market conditions [1][2][4][5]. Financial Performance - Centene reported a GAAP diluted loss per share of -$0.51 for Q2 2025, primarily due to a reduction in the company's net 2025 Marketplace risk adjustment revenue transfer estimate [4]. - The company withdrew its 2025 financial guidance on July 1, 2025, after a review revealed lower-than-expected market growth and higher morbidity levels than previously assumed, resulting in a stock price drop of over 40% [6]. Legal Issues - A class action lawsuit, Lunstrum v. Centene Corporation, has been filed, representing investors who purchased Centene securities between December 12, 2024, and June 30, 2025, alleging violations of the Securities Exchange Act of 1934 [2][4]. - The lawsuit claims that Centene's leadership misled investors by presenting an overly optimistic view of the company's financial health, despite internal data indicating lower enrollment and higher morbidity rates [5][7]. Market Conditions - Centene's public statements had previously suggested expanding market share and robust business performance, particularly in serving underinsured and uninsured populations, which the lawsuit argues were not aligned with actual operational metrics [5][7]. - A preliminary analysis indicated that more than two-thirds of Centene's Marketplace share showed lower-than-expected enrollment, contradicting the company's optimistic reports [5].
Superior HealthPlan and Centene Foundation Announce Grand Opening of CHDI Multi-Purpose Community Health Center in Uvalde
Prnewswire· 2025-07-28 15:45
Core Insights - A new $16 million multi-purpose community health center has been opened in Uvalde, Texas, managed by Community Health Development, Inc. (CHDI), providing healthcare services, community support, and resources for the local community [1][2]. Group 1: Project Background - The health center was announced following the Robb Elementary School shooting in May 2022, addressing the urgent need for comprehensive physical, behavioral, and emotional health services [3]. - CHDI identified three key initiatives in response to the community's needs: building the new health center, establishing a school-based health center, and creating the Robb Elementary School Dream Scholarship Fund [3]. Group 2: Funding and Community Impact - The center received over $8 million in funding from the Centene Foundation and Superior HealthPlan, which serves one in four individuals in the county [4]. - CHDI serves more than 12,000 people annually in the region, and the new center is expected to fill critical gaps in the healthcare system, making a lasting impact on the health of Uvalde [5][8]. Group 3: Facility Features - The 16,000-square-foot facility includes seven primary medical care examination rooms, three dental operatories, behavioral health services via telehealth, a Class A pharmacy, a medical laboratory, and a community room with a capacity for over 150 people [7]. - Additional features include a tranquility garden honoring the victims of the Robb Elementary School tragedy, office space for Texas Rio Grande Legal Aid, and a college/job preparation training space for students [7]. Group 4: Organizational Background - CHDI, founded in 1983, aims to increase access to primary healthcare and is recognized as a Patient Centered Medical Home, receiving Gold Tier recognition as a Health Center Quality Leader [8]. - Superior HealthPlan, a managed care company under Centene, has been providing healthcare services to Texans for over 25 years, supporting local involvement across all Texas counties [9]. Group 5: Philanthropic Efforts - The Centene Foundation focuses on investing in economically challenged communities, addressing social drivers of health, and improving health equity through healthcare access, social services, and education [10].
Centene's Bottom May Already Be Here - Risk Mitigation In Process
Seeking Alpha· 2025-07-28 15:15
Core Insights - The article emphasizes the importance of conducting personal in-depth research and due diligence before making investment decisions, highlighting the inherent risks involved in trading [3]. Group 1 - The analysis is intended solely for informational purposes and should not be interpreted as professional investment advice [3]. - There is a clear disclaimer regarding the lack of any stock, option, or similar derivative positions in the companies mentioned, indicating a neutral stance [2]. - The article expresses that past performance does not guarantee future results, underscoring the uncertainty in investment outcomes [4].
Centene's Worst Quarter In Years Could Be A Gift
Seeking Alpha· 2025-07-28 14:31
Core Insights - Earnings were disappointing but largely in line with expectations, indicating that the situation was not as severe as initially feared [1] Group 1 - The article discusses the performance of global markets, including macroeconomic factors, international equities, commodities, technology, and cryptocurrencies [1] - The Pragmatic Investor aims to assist investors at all levels by providing a diversified portfolio strategy to preserve and grow wealth [1] - The leader of The Pragmatic Investor, an economist with a decade of experience, emphasizes the importance of building robust investment portfolios [1]
Time To Buy Centene Stock?
Forbes· 2025-07-28 13:25
Core Insights - Centene Corporation reported a surprise loss of $0.16 per share for Q2, missing analyst expectations of $0.23 per share, primarily due to a 540 basis point year-over-year increase in its health benefit ratio to 93% [2] - Despite disappointing results, Centene's stock rose 6% following management's optimistic forecast for improved performance in 2026 [3] - Year-to-date, Centene's stock is down over 50%, but its current price of around $28 presents a compelling buying opportunity due to its low valuation [4] Financial Performance - Centene's revenues grew 22.3% to $48.7 billion in the most recent quarter from $40 billion a year ago, compared to a 4.5% improvement for the S&P 500 [9] - The company has a price-to-sales (P/S) ratio of 0.1, a price-to-free cash flow (P/FCF) ratio of 9.4, and a price-to-earnings (P/E) ratio of 5.4, all significantly lower than the S&P 500 [9] - Operating income over the last four quarters was $1.9 billion, with an operating margin of 1.1%, and net income was $2.5 billion, indicating a net income margin of 1.4% [16] Valuation and Market Position - Centene's current valuation of 0.1x revenues is considered attractive, especially for investors with a 3-5 year horizon [13][14] - The average analyst price target of $44 suggests a potential upside of over 55% from current levels [14] - The company's balance sheet shows a debt figure of $18 billion against a market capitalization of $14 billion, resulting in a debt-to-equity ratio of 130.0% [16] Risk and Resilience - Centene's stock has shown a slightly better performance than the S&P 500 during recent downturns, although it remains a risky investment due to ongoing concerns about rising medical costs [12] - The overall assessment of Centene indicates moderate performance across key parameters: strong growth, extremely weak profitability, weak financial stability, and neutral downturn resilience [17]
The Gross Law Firm Reminds Centene Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 8, 2025 - CNC
Prnewswire· 2025-07-28 12:45
Core Viewpoint - Centene Corporation is facing a class action lawsuit due to allegations of providing misleading statements regarding its enrollment and morbidity rates, leading to a significant drop in stock price after the withdrawal of its 2025 guidance [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Centene's management made overly positive statements while concealing adverse facts about the company's performance [1]. - On July 1, 2025, Centene withdrew its 2025 guidance, revealing that its market growth across 22 states was lower than expected, resulting in a revised guidance of approximately $1.8 billion and an adjusted diluted EPS of $2.75 [1]. - Following this announcement, Centene's stock price plummeted from $56.65 per share to $33.78 per share, marking a decline of 40.4% [1]. Group 2: Class Action Details - The class period for the lawsuit is defined as December 12, 2024, to June 30, 2025, and shareholders are encouraged to register for participation [2]. - The deadline for shareholders to seek lead plaintiff status is September 8, 2025, and there is no cost or obligation to participate in the case [2]. Group 3: Law Firm's Commitment - The Gross Law Firm is dedicated to protecting investors' rights and ensuring companies adhere to responsible business practices [3]. - The firm aims to recover losses for investors who were affected by false or misleading statements that artificially inflated stock prices [3].
CNC LAWSUIT: Centene Corporation Sued for Fraud after Wakely Report – Contact BFA Law by September 8 Court Deadline (NYSE:CNC)
GlobeNewswire News Room· 2025-07-28 12:32
Core Viewpoint - A lawsuit has been filed against Centene Corporation and its senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Company Overview - Centene Corporation is a healthcare company that provides services to consumers enrolled in government-sponsored healthcare programs such as Medicaid and Medicare, as well as those purchasing insurance under the Affordable Care Act [3]. Financial Guidance and Performance - On December 12, 2024, Centene announced financial guidance for fiscal year 2025, claiming stability in earnings despite challenges [4]. - The company increased its 2025 guidance on February 4, 2025, citing enrollment overperformance, and again on April 25, 2025, due to strong growth in enrollment and retention [4]. - However, the actual market conditions showed lower than expected enrollment growth and increased morbidity rates in the majority of the states Centene serves [4]. Stock Performance and Market Reaction - On July 1, 2025, Centene withdrew its previous guidance after an independent actuarial report revealed lower than expected market growth and higher morbidity rates [5]. - Following this news, Centene's stock price plummeted by $22.87 per share, a decline of over 40%, from $56.65 on July 1, 2025, to $33.78 on July 2, 2025 [5].
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Centene Corporation (NYSE: CNC)
GlobeNewswire News Room· 2025-07-28 12:00
NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the "Class") who purchased or acquired the securities of Centene Corporation ("Centene" or the "Company") (NYSE: CNC) between December 12, 2024 and June 30, 2025, inclusive. Should You Join This Class Action Lawsuit? If you purchased or acquired Centene securities, and/or would like to discuss your legal rights and options please visit Centene Co ...
异动盘点0728|恒瑞医药高开10%,博彩股走强;AMD涨2.7%,巴菲特持仓威瑞信涨近7%
贝塔投资智库· 2025-07-28 04:09
Group 1: Hong Kong Stock Market Highlights - New China Life Insurance (01336) rose over 5%, reaching a historical high, while China Life (2628.HK) increased by 4.4%, AIA (1299.HK) by 3.5%, and China Pacific Insurance (2601.HK) by nearly 2% following the release of the 2Q25 predetermined interest rate of 1.99% by the insurance industry association [1] - Heng Rui Pharmaceutical (1276.HK) opened up 10.65% after announcing a global exclusive licensing agreement with GSK for the HRS-9821 project, excluding mainland China and certain regions [1] - Guangshen Railway (00525.HK) saw a peak increase of over 9% after signing a cooperation agreement for the Guangzhou East Station renovation project, with a total investment of approximately 16.66 billion yuan [1] Group 2: Other Notable Stock Movements - MicroPort Medical (00853.HK) surged over 8% as major shareholders agreed to sell a total of 291 million shares to various buyers, including funds under Shanghai Industrial Capital [2] - China Tobacco Hong Kong (06055.HK) rose over 5% following the release of a draft management regulation for domestic duty-free tobacco products by the National Tobacco Monopoly Administration [2] - Shenghua Land (08106) saw its stock price soar over 200% after a share acquisition agreement was reached [2] - Jiufang Zhitu Holdings (09636) increased over 10% after announcing a profit forecast for the first half of the year, expecting a net profit of 830 to 870 million yuan, a turnaround from a net loss of 174 million yuan in the same period last year [2] - Lianlian Digital (02598) rose over 7% as a report highlighted the significant role of third-party payment institutions in cross-border and multi-currency settlement services [2] Group 3: Macau Gaming Sector Performance - Gaming stocks saw a general increase, with Amax Holdings (00880) up 10.39%, Melco International Development (00200) up 5.64%, and Sands China (01928) up 3.25%. UBS reported that the average daily gaming revenue in Macau for the past week was 657 million patacas, a slight decline due to typhoon impacts, but still showing a year-on-year growth of approximately 14% [3] Group 4: US Stock Market Highlights - AMD (AMD.US) rose 2.68% as it achieved a 50% market share in the server CPU market, matching Intel for the first time [4] - Newmont Corporation (NEM.US) increased by 6.89%, reporting a second-quarter earnings per share of $1.85, up from 73 cents year-on-year [5] - Berkshire Hathaway's holding Verisign (VRSN.US) rose 6.67% despite Q2 revenue falling short of market expectations, as the company raised its full-year revenue guidance [5] - Tesla (TSLA.US) increased by 3.52% with plans to launch Robotaxi services in San Francisco [6]
CNC Investors with Losses Have Opportunity to Lead Centene Corporation Securities Fraud Lawsuit
Prnewswire· 2025-07-27 21:25
Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Centene Corporation securities between December 12, 2024, and June 30, 2025, due to alleged misleading statements regarding the company's financial performance and enrollment rates [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that Centene's management provided investors with overly positive information regarding expected revenue guidance and adjusted diluted earnings per share (EPS) for the 2025 fiscal year [5]. - Defendants allegedly made confident statements about Centene's enrollment and morbidity rates, while concealing material adverse facts about the true state of these metrics [5]. Group 2: Participation Information - Investors who purchased Centene common stock during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm directly for more information [3][6]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked highly in terms of the number of securities class action settlements and has recovered hundreds of millions of dollars for investors [4].